I-MAB ADR IMAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
-
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
-
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
-
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
-
I-Mab to Release 1H 2024 Financial Results on August 28, 2024
-
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
-
I-Mab Announces Leadership Transitions
-
ADRs Slump; FLJ Group Declines 21%
Trading Information
- Previous Close Price
- $1.30
- Day Range
- $1.34–1.41
- 52-Week Range
- $0.99–2.54
- Bid/Ask
- $1.36 / $1.39
- Market Cap
- $107.83 Mil
- Volume/Avg
- 231,455 / 274,137
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 106.55
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 8.54%
Company Profile
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 220
- Website
- https://www.i-mabbiopharma.com
Valuation
|
Metric
|
IMAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.46 |
Price/Sales | 106.55 |
Price/Cash Flow | — |
Price/Earnings
IMAB
Financial Strength
|
Metric
|
IMAB
|
|---|---|
Quick Ratio | 14.85 |
Current Ratio | 16.50 |
Interest Coverage | — |
Quick Ratio
IMAB
Profitability
|
Metric
|
IMAB
|
|---|---|
Return on Assets (Normalized) | −39.85% |
Return on Equity (Normalized) | −54.02% |
Return on Invested Capital (Normalized) | −53.84% |
Return on Assets
IMAB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nmhbpbmxmz | Vnx | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rwncbxcc | Wkvfh | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mtltnnqhg | Hzkns | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dssjtvhg | Gmcpp | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Fcwthrjxn | Gjzr | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Kqvpbkv | Rxkvb | $29.2 Bil | |||
| Moderna Inc
MRNA
| Rggwrkwvg | Ypdj | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Smwnnqrc | Bzc | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gtgmmbsc | Bkgtzw | $13.2 Bil | |||
| Incyte Corp
INCY
| Ppwnqdlb | Bxzycn | $13.0 Bil |
United States